Innoviva (INVA) Other Non Operating Income (2011 - 2026)
Innoviva's (INVA) quarterly Other Non Operating Income came in at -$366000.0 in Q1 2026, up 63.25% YoY from -$224191.9 in Q1 2025, and up 83.75% on a QoQ basis from -$2.3 million in Q3 2025.
Analysis
Innoviva (INVA) Other Non Operating Income (2011 - 2026) Analysis & Trends
Innoviva (INVA) has 16 years of Other Non Operating Income data on file, last reported at -$366000.0 in Q1 2026.
- Quarterly Other Non Operating Income rose 63.25% year-over-year to -$366000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.4 million (up 30.61% YoY) and the FY2025 annual result came in at $324000.0, up 260.0% from the prior year.
- Other Non Operating Income grew to -$366000.0 in Q1 2026, from -$2.3 million in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $266.7 million in Q3 2022 to a low of -$4.3 million in Q3 2023.
- A 5-year average of $20.8 million and a median of -$1.1 million in 2024 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2023 — Other Non Operating Income plunged 438.4% — and 2026, when it jumped 63.25%.
- Tracing INVA's Other Non Operating Income over 5 years: stood at $266.7 million in 2022, then slumped by 101.61% to -$4.3 million in 2023, then gained by 27.19% to -$3.1 million in 2024, then rose by 27.89% to -$2.3 million in 2025, then jumped by 83.75% to -$366000.0 in 2026.
- The last three Other Non Operating Income figures came in at -$366000.0 (Q1 2026), -$2.3 million (Q3 2025), and -$777000.0 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Innoviva | 1.56 Bn | 984.81 Mn | 90.62 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -15,000.00 |
| Mar 31, 2026 | -366,000.00 |
| Sep 30, 2025 | -2.25 Mn |
| Jun 30, 2025 | -777,000.00 |
| Mar 31, 2025 | -996,000.00 |
| Sep 30, 2024 | -3.12 Mn |
| Jun 30, 2024 | -973,000.00 |
| Mar 31, 2024 | -1.24 Mn |
| Sep 30, 2023 | -4.29 Mn |
| Jun 30, 2023 | -1.90 Mn |
| Mar 31, 2023 | -1.35 Mn |
| Sep 30, 2022 | 266.70 Mn |
| Jun 30, 2022 | -528,000.00 |
| Mar 31, 2022 | -20.66 Mn |
| Sep 30, 2021 | -2.04 Mn |
| Jun 30, 2021 | -951,000.00 |
| Mar 31, 2021 | -433,000.00 |
| Dec 31, 2020 | -433,000.00 |
| Sep 30, 2020 | -13,000.00 |
| Jun 30, 2020 | 30,000.00 |